

# Nerina Denaro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6513598/publications.pdf>

Version: 2024-02-01

60  
papers

1,333  
citations

471061

17  
h-index

360668

35  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2277  
citing authors

#	ARTICLE	IF	CITATIONS
1	In reply to immune desert in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment. <i>Oral Oncology</i> , 2022, 124, 105640.	0.8	1
2	Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression. <i>Vaccines</i> , 2022, 10, 78.	2.1	14
3	Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions. <i>Cells</i> , 2022, 11, 32.	1.8	6
4	Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2021, 9, 235.	2.1	3
5	Effect of moderate physical exercise on the immune system modulation in patients with breast cancer during preoperative chemotherapy: The NEO-RUNNER study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 581-581.	0.8	0
6	Cytokines performance during nivolumab treatment: A subgroup analysis of NIVACTOR study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18008-e18008.	0.8	0
7	Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis. <i>Cancer Management and Research</i> , 2021, Volume 13, 3973-3980.	0.9	7
8	Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103345.	2.0	9
9	Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review. <i>European Journal of Case Reports in Internal Medicine</i> , 2021, 8, 002639.	0.2	2
10	Complete response to immunotherapy in sinonasal undifferentiated carcinoma. <i>Tumori</i> , 2021, 107, NP101-NP104.	0.6	9
11	P-89 Cytokines behaviour during nivolumab treatment. A subgroup analysis of NIVACTOR study. <i>Oral Oncology</i> , 2021, 118, 8.	0.8	1
12	Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). <i>Oncology</i> , 2020, 98, 763-770.	0.9	9
13	Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy. <i>Tumori</i> , 2020, 106, 427-431.	0.6	1
14	Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC). <i>Oral Oncology</i> , 2020, 107, 104801.	0.8	3
15	Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach. <i>Current Opinion in Oncology</i> , 2020, 32, 203-209.	1.1	8
16	Metastatic disease in head & neck oncology. <i>Acta Otorhinolaryngologica Italica</i> , 2020, 40, S1-S86.	0.7	83
17	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. <i>Dysphagia</i> , 2019, 34, 52-62.	1.0	9
18	Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature. <i>Oncology</i> , 2019, 97, 206-210.	0.9	8

#	ARTICLE	IF	CITATIONS
19	In response to Ham et al.: Antibiotics effect on outcome in head and neck cancer. <i>European Journal of Cancer</i> , 2019, 117, 119-120.	1.3	1
20	Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study. <i>Oral Oncology</i> , 2019, 97, 99-104.	0.8	3
21	How I treat squamous ENT cancer. <i>ESMO Open</i> , 2019, 4, e000542.	2.0	4
22	Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression. <i>Head and Neck</i> , 2019, 41, E42-E47.	0.9	10
23	Long noncoding RNA as regulators of cancer immunity. <i>Molecular Oncology</i> , 2019, 13, 61-73.	2.1	131
24	Knowing the tumour microenvironment to optimise immunotherapy. <i>Acta Otorhinolaryngologica Italica</i> , 2019, 39, 2-8.	0.7	16
25	Pros and Cons of the New Edition of TNM Classification of Head and Neck Squamous Cell Carcinoma. <i>Oncology</i> , 2018, 95, 202-210.	0.9	24
26	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT) treated with cyclophosphamide. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 47-52.	0.9	12
27	DUSP2 methylation is a candidate biomarker of outcome in head and neck cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 271-271.	0.7	8
28	Immunotherapy in Head and Neck Squamous Cell Cancer. <i>Clinical and Experimental Otorhinolaryngology</i> , 2018, 11, 217-223.	1.1	18
29	The TRANSERI study: Effect of eribulin (E) on circulating TGF $\beta$ 2 and TNF $\alpha$ in metastatic breast cancer (mBC) patients (pts) - Relationship with outcome. <i>Journal of Clinical Oncology</i> , 2018, 36, e24129-e24129.	0.8	0
30	Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 573-579.	2.0	44
31	Head and neck cancer: improving outcomes with a multidisciplinary approach. <i>Cancer Management and Research</i> , 2017, Volume 9, 363-371.	0.9	150
32	Nab-paclitaxel in clinical practice: Preliminary data from the mantel study. <i>Journal of Clinical Oncology</i> , 2017, 35, e12561-e12561.	0.8	0
33	P16 Cutoff in Head and Neck Squamous Cell Carcinoma: Correlation between Tumor and Patient Characteristics and Outcome. <i>International Journal of Biological Markers</i> , 2016, 31, 44-52.	0.7	2
34	Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience. <i>Clinical and Experimental Otorhinolaryngology</i> , 2016, 9, 287-297.	1.1	118
35	Correlation of TP53 and MDM2 Genotypes and Clinical Outcome in Platinum-Treated Head and Neck Cancer Patients with More than 10 Years' Follow-Up. <i>International Journal of Biological Markers</i> , 2016, 31, 183-192.	0.7	7
36	E1 Detection as Prognosticator in Human Papillomavirus-Positive Head and Neck Cancers. <i>International Journal of Biological Markers</i> , 2016, 31, 163-172.	0.7	2

#	ARTICLE	IF	CITATIONS
37	T memory cells in the tumor invasive margins affect survival in colon cancer (CC) but not in breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, e23104-e23104.	0.8	0
38	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 95, 191-213.	2.0	33
39	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 167-182.	2.0	46
40	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 372-384.	2.0	95
41	Prognostic value of HPV detection with three primer sets in 255 Head-Neck cancers.. Journal of Clinical Oncology, 2015, 33, 6045-6045.	0.8	0
42	State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013. Oncology, 2014, 86, 212-229.	0.9	61
43	Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e1-30.e7.	0.8	6
44	A systematic review of current and emerging approaches in the field of larynx preservation. Radiotherapy and Oncology, 2014, 110, 16-24.	0.3	47
45	Extraordinary Potential of High Technologies Applications: A Literature Review and a Model of Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Prognosis. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2014, 03, 235-240.	0.3	0
46	Abstract 1875: HPV16 detection by PCR in serum of HNSCC patients and comparison with primary tumour tissue. , 2014, , .		0
47	Non coding RNAs in head and neck squamous cell carcinoma (HNSCC): a clinical perspective. Anticancer Research, 2014, 34, 6887-96.	0.5	25
48	Strategies for Non-Resectable Head and Neck Cancer. Current Treatment Options in Oncology, 2013, 14, 492-504.	1.3	12
49	The Role of Neck Dissection after Radical Chemoradiation for Locally Advanced Head and Neck Cancer: Should We Move Back?. Oncology, 2013, 84, 174-185.	0.9	9
50	Management of 'In-Field' Skin Toxicity in Head and Neck Cancer Patients Treated with Combined Cetuximab and Radiotherapy. Oncology, 2013, 85, 257-261.	0.9	11
51	The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. OncoTargets and Therapy, 2013, 9, 1231.	1.0	39
52	Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations. Clinical and Experimental Otorhinolaryngology, 2013, 6, 117.	1.1	106
53	The Role of Antiangiogenic Agents in the Treatment of Head and Neck Cancer. Oncology, 2012, 83, 108-116.	0.9	15
54	The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy. Supportive Care in Cancer, 2012, 20, 2141-2147.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 1051-1057.	0.8	44
56	MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 602-607.	0.8	9
57	Postoperative Therapy in Head and Neck Cancer: State of the Art, Risk Subset, Prognosis and Unsolved Questions. <i>Oncology</i> , 2011, 81, 21-29.	0.9	23
58	Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. <i>Radiation Oncology</i> , 2011, 6, 162.	1.2	10
59	Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives. <i>Cancer Biology and Therapy</i> , 2009, 8, 206-212.	1.5	10
60	The Need to Deepen the Abscopal Effect and Synergy among Radiotherapy and Immunotherapy. <i>International Journal of Radiology and Radiation Oncology</i> , 0, , 019-020.	0.1	0